Skip to main content
. 2021 Jul 22;147(11):3299–3312. doi: 10.1007/s00432-021-03743-y

Fig. 1.

Fig. 1

MSI-1 is associated with survival outcomes in breast cancer patients. Across all breast cancer patients (left column), higher than median MSI-1 expression results in decreased distant metastasis-free survival (DMFS, hazard ratio [HR] = 1.16, p = 0.0016) and disease-free survival (DFS, HR = 1.07, p = 0.042) and tends to decrease overall survival (OS, HR = 1.06, p = 0.22). Similarly, in the estrogen receptor (ER)-positive group (right column), greater than median MSI-1 expression is associated with decreased DMFS (HR = 1.15, p = 0.016), DFS (HR = 1.09, p = 0.038) and OS (HR = 1.12, p = 0.038). Analyses (visualization and log-rank tests) were performed using the bc-GenExMiner tool (Jézéquel et al. 2012)